Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1973

Founded1973

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

105.78B

Market cap105.78B

Price-Earnings ratio

22.74

Price-Earnings ratio22.74

Dividend yield

3.98%

Dividend yield3.98%

Average volume

4.39M

Average volume4.39M

High today

$45.29

High today$45.29

Low today

$44.23

Low today$44.23

Open price

$44.82

Open price$44.82

Volume

15.10M

Volume15.10M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$39.07

52 Week low$39.07

SNY News

Benzinga 1d

Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increase...

The Wall Street Journal 1d

Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Seeking Alpha 2d

Sanofi lifts profit outlook on strong Dupixent sales

Sanofi (SNY) raised its full-year 2026 guidance after reporting stronger-than-expected third-quarter results, supported by robust growth in its pharmaceutical l...

Analyst ratings

50%

of 10 ratings

Buy

50%

Hold

50%

Sell

More SNY News

The Wall Street Journal 2d

Sanofi CEO Sets Sights on Deals to Drive Turnaround

Sanofi attributed the guidance upgrade to its strong commercial and financial momentum. Sylvain Thomas / Agence France-Presse / Getty Images Sanofi’s SAN 0.85...

TipRanks 2d

Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The Phase 1 study “Phase 1, Single Center, Open-label, R...

Simply Wall St 4d

Why Recursion Pharmaceuticals Stock Is Up 6.6% And What's Next

Recursion Pharmaceuticals reported that Sanofi has optioned the first development candidate from their AI-driven collaboration, triggering a US$10 million miles...

24/7 Wall St. 5d

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings

Investing Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings Regeneron (NASDAQ:REGN | REGN Price Prediction) reports...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.